阿比美替尼治疗胰腺癌的第二阶段数据后，免疫工程急剧下降

2026-01-08 05:59

Immuneering Corp. (IMRX) is down ~21% in after-hours trading Wednesday after posting phase 2a results on atebimetinib as a first-line treatment for pancreatic cancer.
The biotech reported 64% overall survival at 12 months in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP). The company noted that the standard of care benchmark at 12 months for overall survival is 35%.
The overall response rate was 39% at 12 months compared to a standard of care of 23%. Median progression-free survival of 8.5 months compares to 5.5 months with standard of care
Immuneering noted that only two categories of adverse events were seen at the Grade 3 level in more than 10% of patients, neutropenia and anemia.
Although results for atebimetinib were good, investors may be comparing it to other first-line pancreatic cancer treatments in development, such as Verastem's (VSTM) avutometinib plus defactinib combo and Revolution Medicines' (RVMD) daraxonarasib. Avuto + defac previously reported an 83% overall response rate, while for daraxonarasib, it was 55%. However, the Verastem and Revolution Medicines results had shorter median follow-up durations.

More on Immuneering